The effect of variable cigarette consumption on the interaction with clozapine and olanzapine

European Journal of Clinical Pharmacology

Volumn 62, Issue 12, 2006, Pages 1049-1053

  Haslemo, Tore ^a   Eikeseth, Per Haakon ^b   Tanum, Lars ^a   Molden, Espen ^a   Refsum, Helge ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b LOVISENBERG DIAKONALE HOSPITAL   (Norway)

Author keywords

Clozapine; Olanzapine; Smoking

Indexed keywords

CLOZAPINE; OLANZAPINE;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING HABIT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; INPATIENTS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MIDDLE AGED; NURSING HOMES; SCHIZOPHRENIA; SMOKING;

EID: 33751252806     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0209-9     Document Type: Article

References (25)

1. Aleman A, Kahn RS, Selten JP (2003) Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 60:565-571
2. Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML et al (2004) Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 26:167-170
3. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P et al (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped Patients. Ther Drug Monit 27:539-543
4. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193
5. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S et al (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23:119-127
6. de LJ, Diaz FJ (2005) A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76:135-157
7. Gex-Fabry M, Balant-Gorgia AE, Balant LP (2003) Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25:46-53
8. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
9. Khan AY, Preskorn SH (2005) Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 11:289-301
10. Lohr JB, Flynn K (1992) Smoking and schizophrenia. Schizophr Res 8:93-102
11. Meyer JM (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 21:569-574
12. Olesen OV, Linnet K (2001) Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 41:823-832
13. Perry PJ, Argo TR, Carnahan RM, Lund BC, Holman TL et al (2005) The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 25:250-254
14. Perry PJ, Bever KA, Arndt S, Combs MD (1998) Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44:733-738
15. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S et al (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55(Suppl B):133-136
16. Raaska K, Raitasuo V, Laitila J, Neuvonen PJ (2004) Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 94:13-18
17. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT et al (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24:70-78
18. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449
19. Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT (1999) Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 85:244-246
20. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F (2002) Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24:518-526
21. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN et al (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162:1281-1290
22. Tyson PJ, Roberts KH, Mortimer AM (2004) Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 114:593-611
23. Van der Weide J, Steijns LS, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13:169-172
24. Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W (2005) Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 25:570-574
25. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 17:141-143